866-997-4948(US-Canada Toll Free)

Overactive Bladder Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Oncology

No. of Pages : 132 Pages


Global Markets Directs, \'Overactive Bladder Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Overactive Bladder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Overactive Bladder. 

Overactive Bladder Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Overactive Bladder.
  • A review of the Overactive Bladder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Overactive Bladder pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Overactive Bladder.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Overactive Bladder pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Overactive Bladder Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Overactive Bladder 8
Overactive Bladder Therapeutics under Development by Companies 10
Overactive Bladder Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Overactive Bladder Therapeutics Products under Development by Companies 18
Overactive Bladder Therapeutics Products under Investigation by Universities/Institutes 21
Companies Involved in Overactive Bladder Therapeutics Development 22
Allergan, Inc. 22
GlaxoSmithKline plc 23
Merck & Co., Inc. 24
Dainippon Sumitomo Pharma Co., Ltd. 25
Ipsen S.A. 26
American Oriental Bioengineering, Inc. 27
Astellas Pharma Inc. 28
Laboratoires Pierre Fabre SA 29
Recordati S.p.A. 30
Teva Pharmaceutical Industries Limited 31
Addex Pharmaceuticals 32
Hisamitsu Pharmaceutical Co., Inc. 33
Urigen Pharmaceuticals, Inc. 34
Plethora Solutions Holdings plc 35
KeyNeurotek Pharmaceuticals AG 36
Respiratorius AB 37
Hydra Biosciences, Inc. 38
Targacept, Inc. 39
Laboratorios SALVAT S.A. 40
FemmePharma Global Healthcare, Inc. 41
Mt Cook Pharma. Inc. 42
Ion Channel Innovations, LLC 43
Overactive Bladder Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Combination Products 45
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
SMP-986 - Drug Profile 50
mirabegron - Drug Profile 51
mirabegron - Drug Profile 53
APT - Drug Profile 55
REC-0422 - Drug Profile 56
REC-1819 - Drug Profile 57
solifenacin succinate - Drug Profile 58
dexmecamylamine - Drug Profile 60
oxybutynin - Drug Profile 62
PSD-506 - Drug Profile 63
abobotulinumtoxinA - Drug Profile 65
URG-302 - Drug Profile 67
XEN-D0501 - Drug Profile 68
solabegron hydrochloride - Drug Profile 69
KN-203 - Drug Profile 71
MK-4618 - Drug Profile 72
onabotulinumtoxinA - Drug Profile 73
MCP-202 - Drug Profile 75
AGN-214868 - Drug Profile 76
MCP-101 - Drug Profile 77
AOBO-001 - Drug Profile 78
(pilocarpine + tolterodine tartrate) - Drug Profile 80
bryophyllum pinnatum - Drug Profile 82
oxybutynin - Drug Profile 83
ADX-71441 - Drug Profile 84
HC-067047 - Drug Profile 85
pVAX-hSlo - Drug Profile 86
Tarafenacin - Drug Profile 88
TD-9594 - Drug Profile 89
mirabegron + solifenacin succinate - Drug Profile 90
mequitazine - Drug Profile 92
oxybutynin - Drug Profile 93
tolterodine tartrate - Drug Profile 94
oxybutynin - Drug Profile 95
GABABR PAM - Drug Profile 97
diltiazem hydrochloride - Drug Profile 98
REC-0438 - Drug Profile 99
TRK-380 - Drug Profile 100
GSK-1016790A - Drug Profile 101
Overactive Bladder Therapeutics Drug Profile Updates 103
Overactive Bladder Therapeutics Discontinued Products 117
Overactive Bladder Therapeutics - Dormant Products 118
Overactive Bladder Product Development Milestones 121
Featured News & Press Releases 121

Appendix 128
Methodology 128
Coverage 128
Secondary Research 128
Primary Research 128
Expert Panel Validation 128
Contact Us 129
Disclaimer 129

List of Table


Number of Products Under Development for Overactive Bladder, H1 2013 11
Products under Development for Overactive Bladder Comparative Analysis, H1 2013 12
Number of Products under Development by Companies, H1 2013 14
Number of Products under Development by Companies, H1 2013 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2013 16
Comparative Analysis by Late Stage Development, H1 2013 17
Comparative Analysis by Mid Clinical Stage Development, H1 2013 18
Comparative Analysis by Early Clinical Stage Development, H1 2013 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 20
Products under Development by Companies, H1 2013 21
Products under Development by Companies, H1 2013 (Contd..1) 22
Products under Development by Companies, H1 2013 (Contd..2) 23
Products under Investigation by Universities/Institutes, H1 2013 24
Allergan, Inc., H1 2013 25
GlaxoSmithKline plc, H1 2013 26
Merck & Co., Inc., H1 2013 27
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 28
Ipsen S.A., H1 2013 29
American Oriental Bioengineering, Inc., H1 2013 30
Astellas Pharma Inc., H1 2013 31
Laboratoires Pierre Fabre SA, H1 2013 32
Recordati S.p.A., H1 2013 33
Teva Pharmaceutical Industries Limited, H1 2013 34
Addex Pharmaceuticals, H1 2013 35
Hisamitsu Pharmaceutical Co., Inc., H1 2013 36
Urigen Pharmaceuticals, Inc., H1 2013 37
Plethora Solutions Holdings plc, H1 2013 38
KeyNeurotek Pharmaceuticals AG, H1 2013 39
Respiratorius AB, H1 2013 40
Hydra Biosciences, Inc., H1 2013 41
Targacept, Inc., H1 2013 42
Laboratorios SALVAT S.A., H1 2013 43
FemmePharma Global Healthcare, Inc., H1 2013 44
Mt Cook Pharma. Inc., H1 2013 45
Ion Channel Innovations, LLC, H1 2013 46
Assessment by Monotherapy Products, H1 2013 47
Assessment by Combination Products, H1 2013 48
Assessment by Stage and Route of Administration, H1 2013 50
Assessment by Stage and Molecule Type, H1 2013 52
Overactive Bladder Therapeutics Drug Profile Updates 106
Overactive Bladder Therapeutics Discontinued Products 120
Overactive Bladder Therapeutics Dormant Products 121
Overactive Bladder Therapeutics Dormant Products (Contd..1) 122
Overactive Bladder Therapeutics Dormant Products (Contd..2) 123

List of Chart


Number of Products under Development for Overactive Bladder, H1 2013 11
Products under Development for Overactive Bladder Comparative Analysis, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 16
Late Stage Products, H1 2013 17
Mid Clinical Stage Products, H1 2013 18
Early Clinical Stage Products, H1 2013 19
Discovery and Pre-Clinical Stage Products, H1 2013 20
Assessment by Monotherapy Products, H1 2013 47
Assessment by Combination Products, H1 2013 48
Assessment by Route of Administration, H1 2013 49
Assessment by Stage and Route of Administration, H1 2013 50
Assessment by Molecule Type, H1 2013 51
Assessment by Stage and Molecule Type, H1 2013 52

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *